General AML

ESH 2019 | What are the new concepts to target cancer stem cells in AML?

L:

The AML Global Portal were delighted to speak to Ravi Majeti, Stanford University School of Medicine, Stanford, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Ravi Majeti: What are the new concepts to target cancer stem cells in AML?

Ravi Majeti discusses different targets for therapies in AML. These include the self-renewal signaling pathways (e.g. Hedgehog and Wnt) and immunological approaches (e.g. targeting cell surface receptors like CD123 with chimeric antigen receptor [CAR] T-cell therapy). He also raises questions regarding the role of measurable residual disease (MRD).

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative